Beneficial effect of continuous positive airway pressure on lipid profiles in obstructive sleep apnea: a meta-analysis

Sleep and Breathing

Volumn 19, Issue 3, 2015, Pages 809-817

  Lin, Ming Tzer ^a,b,c   Lin, Hsien Ho ^b   Lee, Pei Lin ^c   Weng, Pei Hsuan ^b,d   Lee, Chang Chun ^b   Lai, Ting Chun ^b   Liu, Wei ^b   Chen, Chi Ling ^b,e  

^a Hsiao Chung Cheng Hospital   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d TAIWAN ADVENTIST HOSPITAL   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Cholesterol; Continuous positive airway pressure; Lipoproteins; Meta analysis; Sleep apnea, obstructive; Triglycerides

Indexed keywords

ANTILIPEMIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; LIPID;

ARTICLE; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; DAYTIME SOMNOLENCE; DIABETES MELLITUS; DYSLIPIDEMIA; HUMAN; HYPERTENSION; LIPID ANALYSIS; META ANALYSIS; PATIENT COMPLIANCE; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SLEEP DISORDERED BREATHING; SYSTEMATIC REVIEW; THERAPY EFFECT; BLOOD; SLEEP APNEA, OBSTRUCTIVE; TREATMENT OUTCOME;

CONTINUOUS POSITIVE AIRWAY PRESSURE; HUMANS; LIPIDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SLEEP APNEA, OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 84945749286     PISSN: 15209512     EISSN: 15221709     Source Type: Journal    
DOI: 10.1007/s11325-014-1082-x     Document Type: Article

References (48)

1. Jennum P, Riha RL (2009) Epidemiology of sleep apnoea/hypopnoea syndrome and sleep-disordered breathing. Eur Respir J 33(4):907–914. doi:10.1183/09031936.00180108
2. Eckert DJ, Malhotra A (2008) Pathophysiology of adult obstructive sleep apnea. Proc Am Thorac Soc 5(2):144–153. doi:10.1513/pats.200707-114MG
3. Marin JM, Carrizo SJ, Vicente E, Agusti AG (2005) Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 365(9464):1046–1053. doi:10.1016/s0140-6736(05)71141-7
4. Graham I, Cooney MT, Bradley D, Dudina A, Reiner Z (2012) Dyslipidemias in the prevention of cardiovascular disease: risks and causality. Curr Cardiol Rep 14(6):709–720. doi:10.1007/s11886-012-0313-7
5. Drager LF, Jun J, Polotsky VY (2010) Obstructive sleep apnea and dyslipidemia: implications for atherosclerosis. Curr Opin Endocrinol Diabetes Obes 17(2):161–165. doi:10.1097/MED.0b013e3283373624
6. McArdle N, Hillman D, Beilin L, Watts G (2007) Metabolic risk factors for vascular disease in obstructive sleep apnea: a matched controlled study. Am J Respir Crit Care Med 175(2):190–195. doi:10.1164/rccm.200602-270OC
7. Newman AB, Nieto FJ, Guidry U, Lind BK, Redline S, Pickering TG, Quan SF (2001) Relation of sleep-disordered breathing to cardiovascular disease risk factors: the sleep heart health study. Am J Epidemiol 154(1):50–59
8. Drager LF, Jun JC, Polotsky VY (2010) Metabolic consequences of intermittent hypoxia: relevance to obstructive sleep apnea. Best Pract Res Clin Endocrinol Metab 24(5):843–851. doi:10.1016/j.beem.2010.08.011
9. Mirrakhimov AE, Ali AM (2013) Pathobiology of obstructive sleep apnea-related dyslipidemia: focus on the liver. ISRN Cardiology 2013:687069. doi:10.1155/2013/687069
10. Hedner J, Darpo B, Ejnell H, Carlson J, Caidahl K (1995) Reduction in sympathetic activity after long-term CPAP treatment in sleep apnoea: cardiovascular implications. Eur Respir J 8(2):222–229
11. Buechner N, Zidek W, Eer M, Haske M, Sanner B (2001) Obstructive sleep apnea syndrome. Eff Ther Dyslipidemia Somnologie 5:97–102. doi:10.1046/j.1439-054X.2001.01159.x
12. Michailidis V, Steiropoulos P, Nena E, Papanas N, Maltezos E, Bouros D (2011) Continuous positive airway pressure treatment: effect on serum lipids in patients with obstructive sleep apnoea. Open Cardiovasc Med J 5:231–238. doi:10.2174/1874192401105010231
13. Robinson GV, Pepperell JC, Segal HC, Davies RJ, Stradling JR (2004) Circulating cardiovascular risk factors in obstructive sleep apnoea: data from randomised controlled trials. Thorax 59(9):777–782. doi:10.1136/thx.2003.018739
14. Xu H, Yi H, Guan J, Yin S (2014) Effect of continuous positive airway pressure on lipid profile in patients with obstructive sleep apnea syndrome: a meta-analysis of randomized controlled trials. Atherosclerosis 234(2):446–453. doi:10.1016/j.atherosclerosis.2014.03.034
15. Kohler M, Stoewhas AC, Ayers L, Senn O, Bloch KE, Russi EW, Stradling JR (2011) Effects of continuous positive airway pressure therapy withdrawal in patients with obstructive sleep apnea: a randomized controlled trial. Am J Respir Crit Care Med 184(10):1192–1199. doi:10.1164/rccm.201106-0964OC
16. Sharma SK, Agrawal S, Damodaran D, Sreenivas V, Kadhiravan T, Lakshmy R, Jagia P, Kumar A (2013) Retraction: CPAP for the metabolic syndrome in patients with obstructive sleep apnea. N Engl J Med 369(18):1770. doi:10.1056/NEJMc1313105
17. Dorkova Z, Petrasova D, Molcanyiova A, Popovnakova M, Tkacova R (2008) Effects of continuous positive airway pressure on cardiovascular risk profile in patients with severe obstructive sleep apnea and metabolic syndrome. Chest 134(4):686–692. doi:10.1378/chest. 08-0556
18. Pepperell JC, Ramdassingh-Dow S, Crosthwaite N, Mullins R, Jenkinson C, Stradling JR, Davies RJ (2002) Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised parallel trial. Lancet 359(9302):204–210. doi:10.1016/s0140-6736(02)07445-7
19. Higgins JP, Altman DG, Sterne J AC. (2011) Assessing risk of bias in included studies. In: Higgins JP and Green S, editors. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. http://www.cochrane-handbook.org. Accessed 17 Jul 2014
20. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A (2002) Meta-analyses involving cross-over trials: methodological issues. Int J Epidemiol 31(1):140–149
21. Palmer TM, Peters JL, Sutton AJ, Moreno SG (2008) Contour-enhanced funnel plots for meta-analysis. Stata J 8(2):242–254
22. Phillips CL, Yee BJ, Marshall NS, Liu PY, Sullivan DR, Grunstein RR (2011) Continuous positive airway pressure reduces postprandial lipidemia in obstructive sleep apnea: a randomized, placebo-controlled crossover trial. Am J Respir Crit Care Med 184(3):355–361
23. Comondore VR, Cheema R, Fox J, Butt A, John Mancini GB, Fleetham JA, Ryan CF, Chan S, Ayas NT (2009) The impact of CPAP on cardiovascular biomarkers in minimally symptomatic patients with obstructive sleep apnea: a pilot feasibility randomized crossover trial. Lung 187(1):17–22. doi:10.1007/s00408-008-9115-5
24. Drager LF, Bortolotto LA, Figueiredo AC, Krieger EM, Lorenzi GF (2007) Effects of continuous positive airway pressure on early signs of atherosclerosis in obstructive sleep apnea. Am J Respir Crit Care Med 176(7):706–712. doi:10.1164/rccm.200703-500OC
25. Coughlin SR, Mawdsley L, Mugarza JA, Wilding JP, Calverley PM (2007) Cardiovascular and metabolic effects of CPAP in obese males with OSA. Eur Respir J 29(4):720–727. doi:10.1183/09031936.00043306
26. Craig SE, Kohler M, Nicoll D, Bratton DJ, Nunn A, Davies R, Stradling J (2012) Continuous positive airway pressure improves sleepiness but not calculated vascular risk in patients with minimally symptomatic obstructive sleep apnoea: the MOSAIC randomised controlled trial. Thorax 67(12):1090–1096. doi:10.1136/thoraxjnl-2012-202178
27. Sharma SK, Agrawal S, Damodaran D, Sreenivas V, Kadhiravan T, Lakshmy R, Jagia P, Kumar A (2011) CPAP for the metabolic syndrome in patients with obstructive sleep apnea. N Engl J Med 365(24):2277–2286. doi:10.1056/NEJMoa1103944
28. Borgel J, Sanner BM, Bittlinsky A, Keskin F, Bartels NK, Buechner N, Huesing A, Rump LC, Mugge A (2006) Obstructive sleep apnoea and its therapy influence high-density lipoprotein cholesterol serum levels. Eur Respir J 27(1):121–127. doi:10.1183/09031936.06.00131304
29. Steiropoulos P, Tsara V, Nena E, Fitili C, Kataropoulou M, Froudarakis M, Christaki P, Bouros D (2007) Effect of continuous positive airway pressure treatment on serum cardiovascular risk factors in patients with obstructive sleep apnea-hypopnea syndrome. Chest 132(3):843–851. doi:10.1378/chest. 07-0074
30. Chin KZ, Shimizu K, Nakamura T, Narai N, Masuzaki H, Ogawa Y, Mishima M, Nakao K, Ohi M (1999) Changes in intra-abdominal visceral fat and serum leptin levels in patients with obstructive sleep apnea syndrome following nasal continuous positive airway pressure therapy. Circulation 100(7):706–712
31. Cuhadaroglu C, Utkusavas A, Ozturk L, Salman S, Ece T (2009) Effects of nasal CPAP treatment on insulin resistance, lipid profile, and plasma leptin in sleep apnea. Lung 187(2):75–81. doi:10.1007/s00408-008-9131-5
32. Davies RJ, Turner R, Crosby J, Stradling JR (1994) Plasma insulin and lipid levels in untreated obstructive sleep apnoea and snoring; their comparison with matched controls and response to treatment. J Sleep Res 3(3):180–185
33. Lattimore JL, Wilcox I, Skilton M, Langenfeld M, Celermajer DS (2006) Treatment of obstructive sleep apnoea leads to improved microvascular endothelial function in the systemic circulation. Thorax 61(6):491–495. doi:10.1136/thx.2004.039164
34. Ip MS, Lam KS, Ho C, Tsang KW, Lam W (2000) Serum leptin and vascular risk factors in obstructive sleep apnea. Chest 118(3):580–586
35. Nadeem R, Singh M, Nida M, Waheed I, Khan A, Ahmed S, Naseem J, Champeau D (2014) Effect of obstructive sleep apnea hypopnea syndrome on lipid profile: a meta-regression analysis. J Clin Sleep Med 10(5):475–489. doi:10.5664/jcsm.3690
36. Ambrosetti M, Lucioni AM, Conti S, Pedretti RF, Neri M (2006) Metabolic syndrome in obstructive sleep apnea and related cardiovascular risk. J Cardiovasc Med (Hagerstown) 7(11):826–829. doi:10.2459/01.jcm.0000250873.01649.41
37. Platt AB, Kuna ST, Field SH, Chen Z, Gupta R, Roche DF, Christie JD, Asch DA (2010) Adherence to sleep apnea therapy and use of lipid-lowering drugs: a study of the healthy-user effect. Chest 137(1):102–108. doi:10.1378/chest. 09-0842
38. Last AR, Ference JD, Falleroni J (2011) Pharmacologic treatment of hyperlipidemia. Am Fam Physician 84(5):551–558
39. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97(18):1837–1847
40. Pepin JL, Tamisier R, Barone-Rochette G, Launois SH, Levy P, Baguet JP (2010) Comparison of continuous positive airway pressure and valsartan in hypertensive patients with sleep apnea. Am J Respir Crit Care Med 182(7):954–960. doi:10.1164/rccm.200912-1803OC
41. Chen R, Xiong KP, Lian YX, Huang JY, Zhao MY, Li JX, Liu CF (2011) Daytime sleepiness and its determining factors in Chinese obstructive sleep apnea patients. Sleep Breath 15(1):129–135. doi:10.1007/s11325-010-0337-4
42. Barcelo A, Barbe F, de la Pena M, Martinez P, Soriano JB, Pierola J, Agusti AGN (2008) Insulin resistance and daytime sleepiness in patients with sleep apnoea. Thorax 63(11):946–950
43. Kumor M, Bielicki P, Przybylowski T, Rubinsztajn R, Zielinski J, Chazan R (2011) Three month continuous positive airway pressure (CPAP) therapy decreases serum total and LDL cholesterol, but not homocysteine and leptin concentration in patients with obstructive sleep apnea syndrome (OSAS). Pneumonol Alergol Pol 79(3):173–183
44. Arfoosh R, Hosni A, Adra F, Cohen M, Fulambarker A (2007) Effect of continuous positive airway pressure therapy on high density lipoprotein cholesterol (HDLC) in compliant and noncompliant patients with obstructive sleep apnea. Sleep 30:A156–A156
45. Li J, Thorne LN, Punjabi NM, Sun CK, Schwartz AR, Smith PL, Marino RL, Rodriguez A, Hubbard WC, O’Donnell CP, Polotsky VY (2005) Intermittent hypoxia induces hyperlipidemia in lean mice. Circ Res 97(7):698–706. doi:10.1161/01.RES.0000183879.60089.a9
46. Lam JC, Ip MS (2009) Obstructive sleep apnea and the metabolic syndrome. Expert Rev Respir Med 3(2):177–186. doi:10.1586/ers.09.10
47. Katcher HI, Hill AM, Lanford JL, Yoo JS, Kris-Etherton PM (2009) Lifestyle approaches and dietary strategies to lower LDL-cholesterol and triglycerides and raise HDL-cholesterol. Endocrinol Metab Clin N Am 38(1):45–78. doi:10.1016/j.ecl.2008.11.010
48. Joyeux-Faure M, Tamisier R, Baguet J-P, Dias-Domingos S, Perrig S, Leftheriotis G, Janssens J-P, Trzepizur W, Launois SH, Stanke-Labesque F, Levy PA, Gagnadoux F, Pepin J-L (2014) Response to statin therapy in obstructive sleep apnea syndrome: a multicenter randomized controlled trial. Mediat Inflamm 2014:10. doi:10.1155/2014/423120